Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Outstanding (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Shares Outstanding for 7 consecutive years, with $46.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding fell 10.05% to $46.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $46.8 million, a 10.05% decrease, with the full-year FY2024 number at $45.8 million, up 6.31% from a year prior.
  • Shares Outstanding was $46.8 million for Q3 2025 at 4D Molecular Therapeutics, roughly flat from $46.7 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $52.0 million in Q3 2024 to a low of $26.7 million in Q1 2021.
  • A 5-year average of $39.2 million and a median of $42.0 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: surged 418.75% in 2021, then dropped 10.05% in 2025.
  • 4D Molecular Therapeutics' Shares Outstanding stood at $32.2 million in 2021, then grew by 1.25% to $32.6 million in 2022, then soared by 32.02% to $43.1 million in 2023, then grew by 6.31% to $45.8 million in 2024, then increased by 2.13% to $46.8 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Shares Outstanding are $46.8 million (Q3 2025), $46.7 million (Q2 2025), and $46.3 million (Q1 2025).